News Agency
The Times

Bambusa Therapeutics Presents Positive Preliminary Phase 1 BBT002 Data at American Thoracic Society 2026 (ATS 2026) International Conference and Announces First Patient Dosed in Phase 1b/2a CRSwNP Trial

  • Written by PR Newswire
Bambusa Therapeutics Presents Positive Preliminary Phase 1 BBT002 Data at American Thoracic Society 2026 (ATS 2026) International Conference and Announces First Patient Dosed in Phase 1b/2a CRSwNP Trial

- BBT002 is a next-generation, long-acting bispecific antibody targeting two clinically and commercially validated targets, IL-4Rα and IL-5 -

- Preliminary Phase 1 data demonstrated rapid, deep, and sustained effects on key biomarkers for at least 8 weeks following a single dose, including pSTAT6 inhibition, TARC reduction, and eosinophil...

Read more: Bambusa Therapeutics Presents Positive Preliminary Phase 1 BBT002 Data at American Thoracic...

Executive Recruitment And The Value Of Executive Recruitment Agencies In Modern Hiring

Finding the right leadership talent is one of the most important decisions an organisation can make. Strong leaders influence company culture, business performance, strategic direction, and long-term growth. As competition for experienced executives continues to increase, executive recruitment has become a... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion